地舒单抗作用以及功效

It is a powerful and effective bone resorption inhibitor and a targeted treatment drug for osteoporosis that targets the osteoclast regulatory pathway. In June 2010, the FDA approved denosumab Prolia for the treatment of osteoporosis in postmenopausal women, and was later approved for the treatment of osteoporosis in men, bone loss caused by androgen deprivation therapy for prostate cancer, and bone loss caused by aromatase inhibitor therapy for breast cancer. In 2019, denosumab was approved for marketing in my country. Many patients are not particularly clear about its effects and effects. Let’s take a look at it with our medical companions.

A 1-year double-blind, randomized controlled phase III clinical trial DECIDE compared the effectiveness and safety of denosumab and alendronate. A total of 1189 postmenopausal women were enrolled. The average baseline T-score of the lumbar spine of the enrolled patients was -2.6, and the average age was 64 years old. Patients were randomly divided into: treatment group (60 mg subcutaneous injection of this product, once every 6 months, n = 594), control group (oral alendronate sodium 70 mg, once every 6 months, n = 595). All subjects were supplemented with 500 mg of calcium per day, and the dose of vitamin D was adjusted based on plasma 25-hydroxyvitamin D levels.

After 12 months, it can be observed that the BMD of both groups increased at all detection sites (hip, spine, femoral neck, trochanter, and distal 1/3 of the radius), but the increase in the treatment group was more significant than that of the control group (the primary endpoint of total hip BMD increased by 3.5 and 2.6, respectively, P <0. 000 1). The incidence of adverse reactions was similar between the two groups. A patient survey showed that the majority of patients (77%) preferred to receive subcutaneous denosumab twice a year.

The above is an introduction to its functions and effects. I hope it will be helpful to you.